%0 Journal Article
%T Nivolumab provides improved effectiveness and safety compared with docetaxel as a second©\line treatment for advanced non©\small cell lung cancer: A systematic review and meta©\analysis
%A Dongliang Yu
%A Fengming Yi
%A Jianjun Xu
%A Wenxiong Zhang
%A Yiping Wei
%A Zheng Xu
%J Archive of "Cancer Medicine".
%D 2019
%R 10.1002/cam4.1966
%X As an inhibitor of programmed death©\1 (PD©\1) protein, nivolumab has been shown to be effective in various cancers. We thus conducted this meta©\analysis to compare the relative efficacy of nivolumab vs docetaxel©\based chemotherapy as a second©\line treatment for previously treated advanced non©\small cell lung cancer (NSCLC)
%K chemotherapy
%K docetaxel
%K meta©\analysis
%K nivolumab
%K non©\small cell lung cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382729/